A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study to Investigate the Efficacy, Mechanism of Action, Pharmacokinetics, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 as Monotherapy in Patients With Gastroesophageal Reflux Disease (GERD).

Trial Profile

A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study to Investigate the Efficacy, Mechanism of Action, Pharmacokinetics, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 as Monotherapy in Patients With Gastroesophageal Reflux Disease (GERD).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2012

At a glance

  • Drugs ADX-10059 (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2010 Results presented at the 18th United European Gastroenterology Week.
    • 06 May 2010 Results of the patients evaluated mechanisitically were presented at Digestive Disease Week 2010.
    • 05 May 2010 Results were presented at Digestive Disease Week 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top